Heim-Duthoy K, Peltier G, Awni W
Department of Medicine, Hennepin County Medical Center, College of Pharmacy, University of Minnesota, Minneapolis 55415.
Antimicrob Agents Chemother. 1990 May;34(5):922-3. doi: 10.1128/AAC.34.5.922.
Steady-state pharmacokinetics of oral fleroxacin were studied in six males who had skin or skin structure infections and who were receiving 400 mg of fleroxacin once a day. Blood samples (n = 10) and total urine output were collected during a 24-h dosing interval. Fleroxacin concentrations in serum and urine were determined by high-performance liquid chromatography. The maximum concentration in serum and the time to achieve that maximum were 6.2 +/- 2.2 micrograms/ml and 0.94 +/- 0.62 h, respectively. The absorption half-life, alpha half-life, beta half-life, apparent steady-state volume of distribution, apparent total body clearance, and renal clearance were 0.56 +/- 0.37 h, 0.78 +/- 0.51 h, 10.56 +/- 1.40 h, 0.85 +/- 0.31 liters/kg, 129.2 +/- 19.6 ml/min, and 53.3 +/- 16.7 ml/min, respectively. Fleroxacin disposition in this patient population was similar to that in noninfected volunteers with normal renal function.
对6名患有皮肤或皮肤结构感染且每天接受400毫克氟罗沙星治疗的男性进行了口服氟罗沙星的稳态药代动力学研究。在24小时给药间隔期间采集血样（n = 10）和总尿量。通过高效液相色谱法测定血清和尿液中的氟罗沙星浓度。血清中的最大浓度及达到该最大值的时间分别为6.2±2.2微克/毫升和0.94±0.62小时。吸收半衰期、α半衰期、β半衰期、表观稳态分布容积、表观总体清除率和肾清除率分别为0.56±0.37小时、0.78±0.51小时、10.56±1.40小时、0.85±0.31升/千克、129.2±19.6毫升/分钟和53.3±16.7毫升/分钟。该患者群体中氟罗沙星的处置情况与肾功能正常的未感染志愿者相似。
